+7.9%
QCOM vs MRNA
+511.3%
-503.4%
-41.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | -2.2% | +2.3% | +0.1% |
| 7D | +3.3% | +5.5% | -2.1% | +3.2% |
| 30D | +7.7% | +158.7% | -151.0% | +2.3% |
| 3M | -30.1% | +182.1% | -212.2% | -35.1% |
| 6M | +22.8% | +151.8% | -129.0% | +15.0% |
| YTD | +0.2% | +393.6% | -393.4% | -13.9% |
| 1Y | +7.9% | +499.5% | -491.6% | -10.3% |
| All | +7.9% | +511.3% | -503.4% | -10.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling